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Abstract
The assessment of long-term outcome of functional disability and disease activeness in adult patients with juvenile idiopathic
arthritis appears to be complicated due to the absence of a unified approach to the classification and estimation of disease
activeness, as well as the loss of supervision over a patient because of remission or his/her transition from pediatric to adult
rheumatic service.
The objective of the research was to determine how adults with the history of juvenile idiopathic arthritis fulfill the classification
criteria for adult rheumatic diseases, as well as to assess activeness of these diseases, the degree of functional disorders,
and social activeness of patients in Ukraine.
Materials and methods. Patients with juvenile idiopathic arthritis older than 18 years and with more than 3 years of disease
duration living in different parts of Ukraine were included into the study. Data regarding sociodemographic features, fulfillment
of adult classification criteria, Health Assessment Questionnaire, articular and extra-articular Juvenile Arthritis Damage Index
and disease activity were analyzed.
Results. We observed 122 adult patients with the history of juvenile idiopathic arthritis irrespective of the presence of active
inflammation at the moment of the examination. This group included patients from different regions of Ukraine diagnosed
with juvenile idiopathic arthritis during 1984-2013. An adult rheumatologist examined all patients and the diagnosis was
revised according to the adult classification of rheumatic diseases. Typical diagnostic criteria for rheumatoid arthritis were
estimated in 32.8% of patients, ankylosing spondylitis – in 31.1% of patients, undifferentiated arthritis – in 13.9% of patients,
Still’s disease – in 4.9% of patients, psoriatic arthritis – in 0.8% of patients, steady clinical laboratory remission – in 16.5% of
patients. Most patients (81.8%) with rheumatoid factor positive polyarticular juvenile idiopathic arthritis fell under rheumatoid
arthritis criteria in adulthood, and in 85% of patients with enthesitis-related arthritis as well as 53.8% of patients with extended
oligoarthritis ankylosing spondylitis developed in adulthood. 68.8% of patients with systemic juvenile idiopathic arthritis,
68% of patients with rheumatoid factor negative polyarthritic subtype and 55% of patients with enthesitis-related arthritis
had disability and incapacitation. Minimal disorders of the patients’ general condition according to the Health Assessment
Questionnaire in adult age were found in most subtypes of juvenile idiopathic arthritis classified according to the International
League of Associations for Rheumatology (extended and persistent oligoarthritis, rheumatoid factor positive polyarthritis,
systemic subtype); moderate disorders of the general condition were found in enthesitis-related arthritis and rheumatoid
factor negative polyarthritis. Side effects of juvenile idiopathic arthritis according to the articular Juvenile Arthritis Damage
Index included severe articular damage being most frequently found in systemic and rheumatoid factor positive polyarthritis
subtypes of juvenile idiopathic arthritis, while side effects of juvenile idiopathic arthritis according to the extra-articular Juvenile
Arthritis Damage Index included extra-articular damage being found in systemic and rheumatoid factor negative polyarthritis
subtypes of juvenile idiopathic arthritis, that was confirmed by the assessment of physical health according to the Short Form
Health Survey-36, which was the worst in patients with systemic (40.3±12.6) and rheumatoid factor negative polyarthritis
(38.9±9.4) subtypes of juvenile idiopathic arthritis.
Conclusions. Further research of remote consequences of juvenile idiopathic arthritis in adult age and long-term observation
of such patients require a detailed study to improve diagnostics and provide adequate treatment of rheumatic diseases with
juvenile onset in adult age.
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Problem statement and analysis of the
recent research
The assessment of long-term outcome of functional disability
and disease activeness in adult patients with juvenile idio-
pathic arthritis (JIA) appears to be complicated due to the
absence of a unified approach to the classification and estima-
tion of disease activeness, as well as the loss of supervision
over a patient because of remission or his/her transition from
pediatric to adult rheumatic service. All these facts lead to
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insufficient understanding of JIA clinical presentations by
adult rheumatologists. According to many registers (Portugal,
Germany), up to 56% of patients after reaching 18 years of
age continue to be observed by adult rheumatologists due to
an active disease [1, 2]. In such patients, the diagnosis is often
changed according to adult rheumatology terminology. In
2016, Olivier-Ramos et al. [3] published their observations of
adult patients who were included into the Portuguese register
of patients with juvenile diseases; the researchers examined
symptoms of JIA in childhood and their transformation into
various diseases in adult age. It was the first publication focus-
ing on how patients with JIA fulfill the classification criteria
for adult rheumatic diseases. There is a lack of information
about the social status (including study, professional active-
ness, disablement) of adults with JIA.
Thus, the objective of the research was to determine how
adults with the history of JIA fulfill the classification criteria
for adult rheumatic diseases as well as to assess activeness of
these diseases, the degree of functional disorders, and social
activeness of patients in Ukraine.
1. Materials and methods
We observed 122 adult patients with the history of JIA irre-
spective of the presence of active inflammation at the moment
of the examination. This group included patients from dif-
ferent regions of Ukraine diagnosed with JIA during 1984-
2013. Inclusion criteria were: patients with JIA according
to the 2001 revised International League of Associations for
Rheumatology (ILAR) criteria [4], who at the time of data
analysis were older than 18 years, had a disease duration of
>3 years and available data in adulthood. The control group
included healthy young people of corresponding age and sex.
The patients’ medical documentation was retrospectively ana-
lyzed, i.e. the age of the disease onset, period from the starting
of first clinical signs up to the moment of making diagnosis,
activeness of the disease in its debut and received treatment
in childhood. Upon reaching adulthood, all patients were
examined either as inpatients or outpatients in Oleksandrivska
City Clinical Hospital, Kyiv, Ukraine during the period from
April 2015 to December 2016. The duration of the disease,
education, employment record, the ILAR subtypes, as well
as the presence of rheumatoid factor (RF), anti-citrullinated
protein anti-bodies (ACPA), antinuclear factor (ANF), human
leukocyte antigen (HLA) B27, activeness of the disease in
childhood according to the Juvenile Arthritis Disease Activity
Score (JADAS), number of swollen joints, duration of morn-
ing stiffness, systemic manifestations, presence of uveitis,
rash, fever, the erythrocyte sedimentation rate (ESR) (mm/h),
C-reactive protein (CRP) (mg/l) were estimated. The evalua-
tion of patient and physician’s global assessment of disease
activity (VAS 0-10cm), the Short Form Health Survey-36 (SF-
36) and the Health Assessment questionnaire (HAQ), current
and previous therapy with corticosteroids, disease-modifying
antirheumatic drugs (DMARDs) and immunobiological ther-
apy (IBT) were considered as well. The diagnosis of each
patient was revised according to the adult terminology of
rheumatic diseases: rheumatoid arthritis (RA) (according to
the 2010 ACR-EULAR classification criteria) [5], ankylos-
ing spondylitis (AS) (1984 Modified New York Criteria for
AS) [6], psoriatic arthritis (the CASPAR criteria) [7], Still’s
disease [8], undifferentiated arthritis, remission [12].
We assessed the activeness of the disease in all patients.
Since the JADAS clinical assessment of JIA activeness has
certain limitations of appliance [9], especially in patients with
affected spine, in addition to the JADAS, there were used
specific indices of activeness applied for various diseases in
adult rheumatology, i.e. the DAS28 – for patients with RA
[10], the ASDAS - for ankylosing spondylitis, the DAS44 - for
psoriatic arthritis. The disease was considered as non-active
at the DAS28<2.6, the DAS44<1.6, the ASDAS<1.3 [11, 12,
14-16]. In patients with undifferentiated arthritis, the disease
was considered as non-active in the absence of active arthritis,
fever, rash, serositis, uveitis in normal values of ESR and CRP.
The functional condition of patient was measured according
to the HAQ scale, where minimal disorder was diagnosed at 0
up to 0.5, moderate disorder was diagnosed at 0.5 up to 1.5,
and severe disorder was diagnosed at >1.5.
X-ray examination does not fully show the state of the
musculoskeletal system in JIA, as soft tissues may be often
affected as well [18]. Since extra-articular damage does not
have any valid radiological assessment method in adults with
JIA, we used the integral Juvenile Arthritis Damage Index
(JADI) as a method to measure remote articular (JADI-A) and
extra-articular damage (JADI-E) [19]. The JADI-A included
micrognathia and a severely limited mobility in the cervical
spine and/or peripheral joints, while the JADI-E included
cataracts, muscle atrophy, osteoporosis, aseptic necrosis, stria,
stunting, diabetes mellites development, amyloidosis, etc.
Continuous covariates were expressed in terms of their
mean and standard deviation (SD). Categorical covariates
were described by frequency distribution, and validity of dif-
ferences by means of the t-test. A p value was considered
significant at p<0.05. All analyses were performed using
Statistica 6.0.
2. Results
122 patients, whose demographic and main clinical features
are shown in Table 1, were included into the study. The mean
age at the last registered visit was 23.5±8.5 years, and the
average disease duration was 12.7±8.5 years. The mean delay
in diagnosis was 16.8±26.8 months. Most of the patients
(69.3%) had disease duration longer than 10 years, and in
22.1% of patients, it exceeded 20 years. Most studied pa-
tients (53.3%) were women. Having classified the patients
according to the ILAR subtypes, it was concluded that most
patients had persistent oligoarthritis (25.4%), RF-negative
polyarthritis (20.5%) and enthesitis-related arthritis (16.5%).
It is noteworthy saying that psoriatic arthritis was diagnosed
in no examined patients and undifferentiated arthritis was
found in 4.9% of patients only. The prevalence of antinuclear
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antibodies (ANA), RF, ACPA and HLA B27 are shown in
Table 1. The mean age at the onset of the disease was 9.3±4.8
years. Most patients had partially completed higher education
(47.5%) or obtained complete higher education (31.9%). At
the moment of the examination, 65 patients were students, 40
patients were employed, and 17 patients were not permanently
employed. 42.6% of patients had JIA related disability. The
assessment of the activeness and functional condition showed
that at the moment of the examination the majority of patients
(60.7%) had active disease, although functional activeness
according to the HAQ was mild (0.41±0.5). One third of
patients (30.3%) needed a joint prosthesis which is reflected
in the integral indices of remote JIA consequences – JADI-A
(1.9±4.4), although JADI-E was also high – 0.68±1.4, which
was associated with the side effect of glucocorticoids (GCs).
The analysis of the previous treatment showed that almost
a half of the patients (43.4%) had taken GCs previously or
were taking them at the moment of the examination, 80.3%
of patients received a therapy with one or several DMARDs,
12.3% of patients received IBT. Cumulative dose of GCs
was 7.3±31.8g, cumulative dose of synthetic DMARDs was
5.45±5.5 and cumulative dose of IBT was 4.1±3.6.
An adult rheumatologist examined all patients with the
history of JIA and the diagnosis was revised according to the
adult classification of rheumatic diseases. Table 2 shows the
transformation of different JIA subtypes into adult rheumatic
diseases.
The results of diagnosis revision in 122 adult patients
showed that typical diagnostic criteria for RA were estimated
in 32.8%, AS – in 31.1% of patients, undifferentiated arthritis
– in 13.9% of patients, Still’s disease – in 4.9% of patients,
psoriatic arthritis – in 0.8% of patients, steady clinical labora-
tory remission – in 16.5% of patients. Most patients with RF+
polyarticular JIA (81.8%) fulfilled RA criteria in adulthood,
and in 85% of patients with enthesitis-related arthritis as well
as 53.8% of patients with extended oligoarthritis ankylosing
spondylitis developed in adulthood.
We assessed the activeness of the disease in adulthood;
determined the HAQ score, the JADI index, and disability sta-
tus depending on the ILAR classification system for juvenile
idiopathic arthritis, which is reflected in Table 3.
According to Table 3, 68.8% of patients with systemic JIA,
RF-, 68% of patients with RF- polyarthritic subtype and 55%
of patients with enthesitis-related arthritis had disability and
incapacitation. Minimal disorders of the patients’ general con-
dition according to the HAQ in adult age were found in most
ILAR subtypes of JIA (extended and persistent oligoarthritis,
RF+ polyarthritis, systemic subtype), and moderate disor-
ders of the general condition were found in enthesitis-related
arthritis and RF- polyarthritis. Side effects of JIA according
to the JADI-A included severe articular damage being most
frequently found in systemic and RF+ polyarthritis subtypes
of JIA, while side effects of JIA according to the JADI-E
included extra-articular damage being found in systemic and
RF- polyarthritis subtypes of JIA, that was confirmed by the
assessment of physical health according to the SF-36, which
was the worst in patients with systemic (40.3±12.6) and RF-
polyarthritis (38.9±9.4) subtypes of JIA.
3. Discussion
There is a limited number of long-term observations of pa-
tients with JIA [18, 19], mostly dating back to the pre-biological
era. Our research presented observations of Ukrainian adult
patients with JIA (the mean duration of the disease was 12.8±8.5
years) including 22.1% of patients with disease duration ≥20
years. We investigated that most patients continued to take
DMARDs or undergo IBT, 60.7% of patients had active dis-
ease, 22.9% of the studied patients received IBT in childhood
or adulthood. This exceeded the data of Selvaag AM, et al,
who informed that 41% of patients with JIA had active disease
at the age of 30 years, and another investigation registered
37-43% of patients with active disease [18, 19]. Our data
coincided with the data presented by Oliveira-Ramos F, et
al [3] who registered 67% of patients with active disease in
adulthood. The researchers attribute the higher percentage to
the fact that to assess disease activeness they applied scales
introduced for rheumatic diseases in adulthood. However,
they did not observe patients with persistent oligoarthritis,
which is different from our investigation. Besides, we in-
cluded 16.4% of patients in remission. The study presented
the correspondence of JIA to the classification criteria for
adult rheumatic diseases in adult patients. Only 13.9% of
patients were not classified according to adult disease. 81.8%
of patients with RF+ polyarthritis in childhood could be clas-
sified as RA and 85% of patients with EA as SpA. 25% of
patients with systemic subtype of JIA were classified as Still’s
syndrome in adulthood and 31.3% of patients as RA. Half of
patients (50%) with juvenile undifferentiated arthritis reached
remission in adulthood, 33.3% of patients developed rheuma-
toid arthritis, and 16.7% of patients developed spondyloarthri-
tis. Our investigation, however, did not include patients with
juvenile psoriatic arthritis, which indicates diagnostic inade-
quacy of this subtype in childhood. The majority of patients
with RF- polyarthritis (68%), systemic arthritis (68%), and
enthesitis-related arthritis (55%) had JIA related disability,
which indicated an unfavorable clinical course and inadequate
therapy for these JIA subtypes. The integral JADI of remote
articular and extra-articular damage showed severe articular
damage in patients with systemic JIA and RF+ polyarthritis
and extra-articular damage in patients with systemic and RF-
polyarthritis. This reflected more aggressive course of the
disease in these subtypes and the use of higher dose of GCs.
4. Conclusions
The results of our investigation showed that further research
of remote consequences of JIA in adult age and long-term ob-
servation of such patients require a detailed study to improve
diagnostics and provide adequate treatment of rheumatic dis-
eases with juvenile onset in adult age.
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Table 1. Clinical description of patients with juvenile idiopathic arthritis
Indices Patients, n=122 No. (%)/ mean±SD Control group, n=76
Female 65 (53.3%) 42 (55.2%)
Male 57 (46.7%) 34 (44.7%)
ILAR variant
Persistent oligoarthritis 31 (25.4%)
Extended oligoarthritis 13 (10.7%)
RF-positive oligoarthritis 11 (9.0%)
RF-negative oligoarthritis 25 (20.5%)
Systemic JIA 16 (13.1%)
Enthesitis-related JIA 20 (16.4%)
Psoriatic arthritis 0
Undifferentiated arthritis 6 (4.9%)
Age at the disease onset, years 9.3±4.8
Time of the delay in diagnosis, months 16.8±26.8
Age at last consultation, years 23.5±7.1 20.2±2.5
Duration of the disease, years 12.8±8.5
ANF+ (n=42) 14 (11.5%)
RF+ (n=122) 30 (24.6%)
ACPA + (n=60) 6 (10%)
HLA B27 + (n=122) 33 (27.0%)
Education
Secondary 27 (22.1%)
Partially completed higher 58 (47.5%) 76 (100%)
Higher 39 (31.9%)
Current professional status
Studying 65 (53.3%) 76 (100%)
Employed 40 (32.8%)
Unemployed 17 (13.9%)
Disability due to JIA 58 (42.6%)
Activeness of the disease
Active disease 74 (60.7%)
Inactive disease 48 (39.3%)
Need joint prosthesis 37 (30.3%)
HAQ score 0.41±0.5 0.01±0.1
JADI-A score 1.9±4.4
JADI-E score 0.68±1.4
SF-36 PCS 43.2±12.6 56.4±5.5
Previous treatment
Patients being previously treated with GCs 53 (43.4%)
Patients being previously treated with synthetic DMARDs 98 (80.3%)
Patients who previously underwent IBT 28 (23.0%)
Current treatment
Patients being previously treated with GCs 36 (29.5%)
Patients being previously treated with synthetic DMARDs 88 (72.1%)
Patients undergoing IBT 15 (12.3%)
Cumulative GCs dose (g) n=77 7.3±31.8
Cumulative dose of synthetic DMARDs, years, n=115 5.45±5.5
Cumulative dose of IBT, years, n= 2 4.1±3.6
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